[1] FRIEDEWALD V E, BENNETT J S, CHRISTO J P, et al. AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am J Cardiol, 2010, 106(6):873-884.[2] CANNON C P, CANNON P J. Physiology COX-2 inhibitors and cardiovascular risk. Science, 2012, 336(6087):1386-1387.[3] CONAGHAN P G. A turbulent decade for NSAIDs: Update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int, 2012, 32(6):1491-1502.[4] TRELLE S, REICHENBACH S, WANDEL S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ, 2011, 342:7086.[5] ZHANG F C. Cyclooxygenase-2 selective inhibitors. Chin Pharm J(中国药学杂志), 2011, 46(11):875-876.[6] PATRICIO J P, BARBOSA J P, RAMOS R M, et al. Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: Implications for clinical practice. Clin Drug Investig, 2013, 33(3):167-183.[7] GROSSER T, FRIES S, FITZGERALD G A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest, 2006, 116(1):4-15.[8] YU Y, RICCIOTTI E, SCALIA R, et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med, 2012, 4(132):132.[9] HULISZ D, LAGZDINS M. Drug-induced hypertension. US Pharmacist, 2008, 33(9):11-20. ANTMAN E M, DEMETS D, LOSCALZO J. Cyclooxygenase inhibition and cardiovascular risk. Circulation, 2005, 112(5):759-770. BOMBARDIER C, LAINE L, REICIN A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med, 2000, 343(21):1520-1528. SILVERSTEIN F E, FAICH G, GOLDSTEIN J L, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284(10):1247-1255. AISEN P S, SCHAFER K A, GRUNDMAN M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA, 2003, 289(21):2819-2826. FARKOUH M E, KIRSHNER H, HARRINGTON R A, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet, 2004, 364(9435):675-684. ADAPT RESEARCH GROUP. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials, 2006, 1(7):33. CANNON C P, CURTIS S P, FITZGERALD G A, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet, 2006, 368(9549):1771-1781. SINGH G, FORT J G, GOLDSTEIN J L, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med, 2006, 119(3):255-266. CURFMAN G D, MORRISSEY S, DRAZEN J M. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 2005, 353(26):2813-2814. HOWARD P A, DELAFONTAINE P. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. J Am Coll Cardiol, 2004, 43(4):519-525. SCHIFF M, HOCHBERG M C, OLDENHOF J, et al. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin, 2009, 25(10):2471-2477. CATELLA-LAWSON F, REILLY M P, KAPOOR S C, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 2001, 345(25):1809-1817. MACDONALD T M, WEI L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 2003, 361(9357):573-574. RENDA G, TACCONELLI S, CAPONE M L, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther, 2006, 80(3):264-274. GENGO F M, RUBIN L, ROBSON M, et al. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: Clinical consequences in stroke prophylaxis. J Clin Pharmacol, 2008, 48(1):117-122. SCHUIJT M P, HUNTJENS-FLEUREN H W, DE METZ M, et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol, 2009, 157(6):931-934. OLDENHOF J, HOCHBERG M, SCHIFF M, et al. Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2. Curr Med Res Opin, 2010, 26(6):1497-1504. CAPONE M L, SCIULLI M G, TACCONELLI S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol, 2005, 45(8):1295-1301. GREENBERG H E, GOTTESDIENER K, HUNTINGTON M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol, 2000, 40(12 Pt 2):1509-1515. WILNER K D, RUSHING M, WALDEN C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol, 2002, 42(9):1027-1030. GLADDING P A, WEBSTER M W, FARRELL H B, et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol, 2008, 101(7):1060-1063. LEE W, SUH J W, YANG H M, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J, 2010, 40(7):321-327. ANTMAN E M, BENNETT J S, DAUGHERTY A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation, 2007, 115(12):1634-1642. BORI SEGURA G, HERNANDEZ CRUZ B, GOBBO M, et al.Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: Guidelines from the spanish society of rheumatology and the mexican college of rheumatology. Reumatol Clin, 2009, 5(1):3-12. FINE P G. Treatment guidelines for the pharmacological management of pain in older persons. Pain Med, 2012, 13(suppl 2):57-66. SHAH S, MEHTA V. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management. Postgrad Med J, 2012, 88(1036):73-78. AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC GROUP ON USE OF SELECTIVE AND NONSELECTIVE NONSTEROIDAL ANTIINFLAMMATORY DRUGS. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: An American College of Rheumatology white paper. Arthritis Rheum, 2008, 59(8):1058-1073. XU H M, XU X. Prescription analysis of celecoxib use among outpatients in a general hospital. Chin Pharm J(中国药学杂志), 2009, 44(20):1596-1598. BECKER M C, WANG T H, WISNIEWSKI L, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J, 2009, 157(4):606-612.